FI3641888T3 - Plasminogeenihoito PAI-1-yliekspressioon liittyviin tiloihin - Google Patents
Plasminogeenihoito PAI-1-yliekspressioon liittyviin tiloihin Download PDFInfo
- Publication number
- FI3641888T3 FI3641888T3 FIEP18821458.9T FI18821458T FI3641888T3 FI 3641888 T3 FI3641888 T3 FI 3641888T3 FI 18821458 T FI18821458 T FI 18821458T FI 3641888 T3 FI3641888 T3 FI 3641888T3
- Authority
- FI
- Finland
- Prior art keywords
- plasminogen
- disease
- use according
- condition
- subject
- Prior art date
Links
- 102000013566 Plasminogen Human genes 0.000 title claims 20
- 108010051456 Plasminogen Proteins 0.000 title claims 20
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 title claims 5
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 title claims 5
- 230000002018 overexpression Effects 0.000 title claims 4
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 11
- 210000004204 blood vessel Anatomy 0.000 claims 4
- 208000020832 chronic kidney disease Diseases 0.000 claims 4
- 230000001172 regenerating effect Effects 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 3
- 230000003054 hormonal effect Effects 0.000 claims 3
- 230000002503 metabolic effect Effects 0.000 claims 3
- 201000004384 Alopecia Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010063209 Chronic allograft nephropathy Diseases 0.000 claims 2
- 201000001200 Crouzon syndrome-acanthosis nigricans syndrome Diseases 0.000 claims 2
- 206010018372 Glomerulonephritis membranous Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010036049 Polycystic ovaries Diseases 0.000 claims 2
- 206010002022 amyloidosis Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 206010061989 glomerulosclerosis Diseases 0.000 claims 2
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 2
- 231100000855 membranous nephropathy Toxicity 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 2
- 231100000360 alopecia Toxicity 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 108010087750 lysyl-plasminogen Proteins 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000007634 remodeling Methods 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523901P | 2017-06-23 | 2017-06-23 | |
| PCT/IB2018/000655 WO2018234861A1 (en) | 2017-06-23 | 2018-06-22 | Plasminogen treatment of conditions associated with pai-1 overexpression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3641888T3 true FI3641888T3 (fi) | 2023-12-19 |
Family
ID=64737041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18821458.9T FI3641888T3 (fi) | 2017-06-23 | 2018-06-22 | Plasminogeenihoito PAI-1-yliekspressioon liittyviin tiloihin |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11826404B2 (https=) |
| EP (1) | EP3641888B1 (https=) |
| JP (1) | JP2020524689A (https=) |
| KR (1) | KR20200019217A (https=) |
| CN (1) | CN110831668B (https=) |
| AU (1) | AU2018287316B2 (https=) |
| BR (1) | BR112019027229A2 (https=) |
| CA (1) | CA3068153A1 (https=) |
| CL (1) | CL2019003789A1 (https=) |
| DK (1) | DK3641888T3 (https=) |
| ES (1) | ES2965937T3 (https=) |
| FI (1) | FI3641888T3 (https=) |
| IL (1) | IL271470B2 (https=) |
| MX (1) | MX2019015741A (https=) |
| MY (1) | MY203136A (https=) |
| NZ (1) | NZ760921A (https=) |
| RU (1) | RU2020100080A (https=) |
| SG (1) | SG11201912813SA (https=) |
| TW (1) | TWI868051B (https=) |
| WO (1) | WO2018234861A1 (https=) |
| ZA (1) | ZA202000280B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018107686A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种治疗动脉粥样硬化及其并发症的方法 |
| JP7168990B2 (ja) | 2016-12-15 | 2022-11-10 | タレンゲン インターナショナル リミテッド | 肥満症を予防および治療するための方法および薬物 |
| TWI677348B (zh) | 2016-12-15 | 2019-11-21 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種改善心臟病變的方法 |
| EP4094775A4 (en) * | 2020-02-06 | 2023-04-19 | Talengen International Limited | METHODS AND MEDICATIONS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS |
| US20230173039A1 (en) * | 2020-03-24 | 2023-06-08 | Talengen International Limited | Method and drug for treating alzheimer disease |
| EP4122489A4 (en) * | 2020-03-24 | 2023-04-12 | Talengen International Limited | METHODS AND MEDICATIONS FOR PROMOTING THE BREAKDOWN OF MISFOLDED PROTEIN AND AGGREGATE THEREOF |
| CN115697386A (zh) * | 2020-03-24 | 2023-02-03 | 泰伦基国际有限公司 | 一种治疗帕金森病的方法和药物 |
| CN112174979B (zh) * | 2020-10-27 | 2021-09-07 | 黑龙江中医药大学 | 一种治疗多囊卵巢综合征的药物及其制备方法 |
| WO2026006092A1 (en) * | 2024-06-24 | 2026-01-02 | The Cleveland Clinic Foundation | Enzyme encapsulated nanoparticles |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5520912A (en) * | 1993-07-02 | 1996-05-28 | Immuno Aktiengesellschaft | Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen |
| US6677473B1 (en) * | 1999-11-19 | 2004-01-13 | Corvas International Inc | Plasminogen activator inhibitor antagonists |
| AU3173301A (en) * | 2000-02-11 | 2001-08-20 | European Molecular Biology Laboratory | Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity |
| GB0509438D0 (en) | 2005-05-09 | 2005-06-15 | Prometic Biosciences Ltd | Affinity adsorbets for fibrinogen |
| US8318661B2 (en) * | 2006-08-28 | 2012-11-27 | Omnio Healer Ab | Candidates against infection |
| ES2453496T3 (es) | 2006-08-28 | 2014-04-08 | Omnio Healer Ab | Diana farmacológica novedosa de prevención y tratamiento de enfermedad periodontal, mejora de la cicatrización de heridas periodontales y promoción de la salud oral |
| HK1221725A1 (zh) * | 2013-08-13 | 2017-06-09 | Sanofi | 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途 |
| TWI801331B (zh) * | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| TW201722464A (zh) | 2015-11-10 | 2017-07-01 | 波麥堤克生化科學有限公司 | 用於傷口癒合之纖維蛋白溶酶原給藥方案 |
| JP7242057B2 (ja) | 2016-12-15 | 2023-03-20 | タレンゲン インターナショナル リミテッド | 薬物性腎損傷を予防及び治療するための方法 |
| JP7213552B2 (ja) * | 2016-12-15 | 2023-01-27 | タレンゲン インターナショナル リミテッド | 肝の繊維化を予防及び治療するための方法 |
| JP7168990B2 (ja) * | 2016-12-15 | 2022-11-10 | タレンゲン インターナショナル リミテッド | 肥満症を予防および治療するための方法および薬物 |
-
2018
- 2018-06-15 TW TW107120839A patent/TWI868051B/zh active
- 2018-06-22 DK DK18821458.9T patent/DK3641888T3/da active
- 2018-06-22 BR BR112019027229-1A patent/BR112019027229A2/pt not_active Application Discontinuation
- 2018-06-22 MX MX2019015741A patent/MX2019015741A/es unknown
- 2018-06-22 CN CN201880041573.5A patent/CN110831668B/zh active Active
- 2018-06-22 SG SG11201912813SA patent/SG11201912813SA/en unknown
- 2018-06-22 RU RU2020100080A patent/RU2020100080A/ru unknown
- 2018-06-22 MY MYPI2019007619A patent/MY203136A/en unknown
- 2018-06-22 ES ES18821458T patent/ES2965937T3/es active Active
- 2018-06-22 CA CA3068153A patent/CA3068153A1/en active Pending
- 2018-06-22 KR KR1020207001617A patent/KR20200019217A/ko not_active Ceased
- 2018-06-22 NZ NZ760921A patent/NZ760921A/en unknown
- 2018-06-22 IL IL271470A patent/IL271470B2/en unknown
- 2018-06-22 JP JP2019570806A patent/JP2020524689A/ja active Pending
- 2018-06-22 US US16/625,335 patent/US11826404B2/en active Active
- 2018-06-22 WO PCT/IB2018/000655 patent/WO2018234861A1/en not_active Ceased
- 2018-06-22 AU AU2018287316A patent/AU2018287316B2/en active Active
- 2018-06-22 EP EP18821458.9A patent/EP3641888B1/en active Active
- 2018-06-22 FI FIEP18821458.9T patent/FI3641888T3/fi active
-
2019
- 2019-12-20 CL CL2019003789A patent/CL2019003789A1/es unknown
-
2020
- 2020-01-15 ZA ZA2020/00280A patent/ZA202000280B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020524689A (ja) | 2020-08-20 |
| CL2019003789A1 (es) | 2020-07-10 |
| SG11201912813SA (en) | 2020-01-30 |
| NZ760921A (en) | 2026-01-30 |
| EP3641888B1 (en) | 2023-10-11 |
| EP3641888A4 (en) | 2021-03-10 |
| RU2020100080A3 (https=) | 2021-11-02 |
| IL271470B2 (en) | 2025-07-01 |
| DK3641888T3 (da) | 2024-01-02 |
| KR20200019217A (ko) | 2020-02-21 |
| ZA202000280B (en) | 2021-08-25 |
| MX2019015741A (es) | 2020-11-11 |
| CN110831668A (zh) | 2020-02-21 |
| IL271470A (en) | 2020-01-30 |
| AU2018287316A1 (en) | 2020-02-06 |
| IL271470B1 (en) | 2025-03-01 |
| CN110831668B (zh) | 2024-04-12 |
| MY203136A (en) | 2024-06-10 |
| WO2018234861A1 (en) | 2018-12-27 |
| EP3641888A1 (en) | 2020-04-29 |
| US11826404B2 (en) | 2023-11-28 |
| ES2965937T3 (es) | 2024-04-17 |
| US20210330761A1 (en) | 2021-10-28 |
| TWI868051B (zh) | 2025-01-01 |
| RU2020100080A (ru) | 2021-07-23 |
| BR112019027229A2 (pt) | 2020-07-07 |
| AU2018287316B2 (en) | 2024-09-19 |
| TW201904990A (zh) | 2019-02-01 |
| CA3068153A1 (en) | 2018-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3641888T3 (fi) | Plasminogeenihoito PAI-1-yliekspressioon liittyviin tiloihin | |
| MX2024010140A (es) | Nuevos metodos. | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| ZA201907052B (en) | N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | |
| MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
| IL314347A (en) | Combined treatment of lasmiditan and a CGRP antagonist for use in the treatment of migraine | |
| PH12015502549A1 (en) | Heterocyclic derivatives | |
| WO2016055797A3 (en) | Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation | |
| JP2020524689A5 (https=) | ||
| MX2014003180A (es) | Metodos para tratar vhc. | |
| EP3430057A4 (en) | USE OF APE1 / REF-1 INHIBITORS IN COMBINATION THERAPIES FOR TREATING CANCER | |
| EA201691555A1 (ru) | Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени | |
| CO2022000426A2 (es) | Inhibidores de calicreína plasmática | |
| Arribas et al. | Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| JOP20190112A1 (ar) | علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي | |
| EA201592058A1 (ru) | Применение ландиолола гидрохлорида в длительном лечении тахиаритмии | |
| CN110114079A (zh) | 一种预防和治疗肥胖症的方法和药物 | |
| PH12021551365A1 (en) | Compositions and methods for treating and preventing amyotrophic lateral sclerosis | |
| CA3010788A1 (en) | Methods of administering vasopressors | |
| BR112022009797A2 (pt) | Usos médicos de vaccinia vírus ankara modificado (mva) recombinante com coadjuvante de 4-1bbl | |
| FR2936149B1 (fr) | Utilisation de l'alverine dans le traitement des affections cutanees | |
| EP4385576A3 (en) | Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension | |
| LT4182311T (lt) | 1-metil-1h-pirazol-3-ilo dariniai, skirti naudoti neovaskulinių ligų gydymui | |
| MX2016009226A (es) | Combinaciones farmaceuticas. |